evothyroxine in Nephrotic syndrome
Phase 3
Completed
- Conditions
- ephrotic Syndrome.Nephrotic syndrome
- Registration Number
- IRCT20201112049368N2
- Lead Sponsor
- Artesh University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 82
Inclusion Criteria
idiopathic nephrotic syndrome
Relapse requiring hospitalization
serum TSH grater than 5.5 mIU/
Exclusion Criteria
congenital nephrotic syndrome
Secondary nephrotic syndrome
GFR less than 60 ml/min/1.73 m2
confirmed hypothyroidism before the diagnosis of nephrotic syndrome
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie levothyroxine's effect on nephrotic syndrome relapse duration in pediatric patients?
How does levothyroxine compare to standard-of-care treatments in managing nephrotic syndrome relapse in children?
Are there specific biomarkers that predict response to levothyroxine in steroid-resistant nephrotic syndrome cases?
What are the potential adverse events associated with levothyroxine-steroid combination therapy in pediatric nephrotic syndrome patients?
What other thyroid hormone analogs or combination therapies are being explored for nephrotic syndrome treatment in clinical trials?